Comparative Efficacy of Flunarizine and Propanolol in Pediatric Migraine
Recruiting · NCT07354126 · Interventional (participants receive a specific treatment) · Lead sponsor: Muhammad Aamir Latif
View the official record on ClinicalTrials.gov →Interventions studied
FlunarizinePropranolol
What this trial is about
Flunarizine and propranolol have demonstrated efficacy in reducing migraine frequency across age groups, though evidence in pediatric populations remains limited and inconsistent. Therefore, the current study has been planned to evaluate and compare the effectiveness of flunarizine and propranolol in reducing migraine frequency in children aged 8-15 using the Pediatric Migraine Disability Assessment Scale (PedMIDAS) score.
Who can take part
Age range
8 Years to 15 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Children of any gender
- Aged 8-15 years
- Diagnosed with migraine (with/without aura) per International Classification of Headache Disorders, 3rd Edition (ICHD-3) criteria
- A history of ≥4 migraine attacks/month for the preceding 3 months
- With a PedMIDAS score ≥11 (moderate-to-severe impact)
Exclusion criteria
- Children with secondary headache disorders (e.g., due to infections, trauma, structural brain lesions)
- Known hypersensitivity or contraindications to flunarizine or propranolol
- Presence of cardiovascular disorders (e.g., bradycardia, heart block, hypotension, asthma)
- Non-compliance or inability to attend regular follow-ups
- Participation in another clinical trial within the last 3 months
Where it is running
1 location listed.
- The Children's Hospital Lahore - Lahore, Punjab Province, Pakistan